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ABST RACT
Recent advancements in medical genetics and molecular biology are
reflected in the modern understanding and approach to colorectal carcinoma
(CRC). Understanding the cellular mechanisms and mutational patterns that
promote carcinogenesis could enhance the predictive accuracy of the TNM
classification. Furthermore, this will allow for a much more documented
stratification and tailored oncological treatment. This paper presents an
illustrative case of a relatively young patient (50 years old) with no family
history of cancer who was diagnosed with four synchronous gastrointestinal
(GI) adenocarcinomas displaying a wild type P53, negative BRAF testing,
and mutated MLH1 and PMS2 proteins. This case report contributes to the
relevant literature with a concise review of the role of micro-satellite
instability (MSI), chromosomal instability (CIN), and CpG island
methylator phenotype (CIMP) in carcinogenesis, hereditary and sporadic
gastrointestinal cancers, a discussion over the importance of molecular subtyping in predicting long term outcomes and choosing the most suitable
adjuvant treatment regimen.

Introduction
Recent advancements in medical genetics and
molecular biology are reflected in the modern
understanding and approach to colorectal carcinoma
(CRC). Although the intricacies of the subtle mechanisms
of molecular carcinogenes are not yet fully clarified,
emerging research suggests that similar to breast cancer,
stratification of the patients based on molecular
characteristics or subtypes of CRC could influence
survival, response to treatment, and loco-regional
recurrences.
Nowadays it is unanimously agreed that colonic
carcinogenesis is multifactorial and multi-phased. Based
on proven causal links between etiologic factors, genetic
and epigenetic mutations, and prognostic factors, we
believe that representative cases of multiple primary
familial or hereditary CRC ought to be popularized in
order to reiterate the importance of screening and
genetic counseling in one of the most preventable
malignancies of our times.

Category: Case Presentation
Received: June 01, 2020
Accepted: September 04, 2020
Keywords:
microsatellite instability, synchronous gastrointestinal
cancers, immunohistochemistry, mutational pattern

*Corresponding author:
Cristinel Dumitru Badiu,
Carol Davila University of Medicine and Pharmacy,
Bagdasar Arseni emergency clinical hospital, Bucharest,
Romania, 031298
E-mail: doctorcristianbadiu@yahoo.com

This paper presents an illustrative case of a relatively
young patient (50 years old) with no family history of
cancer who was diagnosed with four synchronous
gastrointestinal (GI) adenocarcinomas displaying multiple
mutational patterns. This case report contributes to the
relevant literature with a concise review of the role of
micro-satellite instability (MSI), chromosomal instability
(CIN), and CpG island methylator phenotype (CIMP) in
carcinogenesis, hereditary and sporadic gastrointestinal
cancers, and a discussion of the importance of molecular
sub-typing in predicting long term outcomes and choosing
the most suitable adjuvant treatment regimen.

Case presentation
A 50 years old patient with no previous personal or
family medical history and no associated comorbidities
presented with recurrent left flank abdominal discomfort to
his general practice doctor who, after an unremarkable
clinical examination, recommended a renal ultrasound
(USS), a complete blood count (CBC), and a urine sample.
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No abnormality was detected except for an incidental renal
cyst of 25/14mm on the right side. Despite these, having a
high index of suspicion of a kidney condition, the GP
ordered a CT scan for further characterization of the renal
tract. The CT exam unexpectedly revealed circumferential
thickening of the splenic flexure extending over 9
centimeters in length, with intense iodophilia, adjacent fat
stranding, and supracentrimetric perilesional lymph nodes
(Figure 1). An additional endoluminal area in the caecum
was described, but with minimal contrast enhancement and
nonspecific features (Figure 2). No lesions suggestive of
liver or bony metastases were reported.

Figure 1. CT scan: splenic flexure tumoral mass, with
severe narrowing of the lumen

Figure 2. CT scan: caecal mass and the ileocaceal-valve
The patient was admitted to our institution with the
presumptive diagnosis of colorectal cancer – possible
synchronous cecal and splenic flexure tumors—for further
investigation and treatment. The clinical exam did not
reveal significant pathological features, the main
subjective sign was transient left hypocondrum and left
flank pain of moderate intensity, and intestinal transit
disturbances, with predominant constipation. The
laboratory tests were normal, except mild anemia (Hb
12mg/dl). For completion of the preoperative evaluation, a
thoracic CT scan (no pulmonary abnormality detected) and
a colonoscopy were performed. The endoscopic
examination revealed a small polypoid lesion in the
sigmoid colon and a circumferential tumor at the splenic
flexure which could not be negotiated. Biopsies showed

moderately differentiated adenocarcinoma (G2) NOS type
for both lesions.
After informed consent was signed, the patient
underwent surgery with a planned exploratory laparotomy
+/- proceed and repeat on table colonoscopy for a full
assessment of the bowel. During the macroscopic intraabdominal assessment, a supracentrimetric lesion was
identified on the greater curvature of the stomach (antral
area), with no connection to the splenic flexure mass.
After a second unsuccessful endoscopic attempt to pass
above the splenic flexure lesion, a minimal colotomy was
performed proximal to the tumor and a purse-string tie was
placed to ensure air-tightness around the colonoscope.
Completion of the colonoscopy revealed a caecal mass
from which frozen sections biopsies confirmed
adenocarcinoma. At this stage, we have identified three
synchronous colonic adenocarcinomas and a suspicious
gastric lesion for which endoscopic frozen sections
confirmed moderately differentiated adenocarcinoma.
Total colectomy with complete mesocolic excision (CME)
and D1 gastrectomy were performed. The postoperative
course was uneventful, with discharge after a week.
The ensuing commented images show the
histopathological features of the tumors. An additional
panel of surrogate gene assessment using IHC
demonstrates a wild type of p53, the absence of MLH1 and
PMS2 proteins, suggesting either a germ line mutation or
inhibition by epigenetic modification (CIMP). Since CIMP
mutations are associated with BRAF mutations, we believe
that a negative BRAF testing is highly indicative of a
possible Lynch syndrome. A positive diagnosis of nonpolyposis hereditary colon cancer (HNPCC) means a 50%
risk for the direct descendants to develop the disease since
it is transmitted in an autosomal dominant manner.
All 4 tumors are solid-type proliferations, with weakmoderate differentiation, with ulcerated surface, and
showing important areas of necrosis and intra-tumoral
hemorrhage, as well as a rich inflammatory infiltrate
formed by polymorphonuclear, lymphocytes and large
histiocytes, which partially shield tumor proliferation at the
level of the invasion front. The lymph nodes analyzed do
not show tumor invasion, but show non-specific chronic
inflammatory features.
Other histopathological findings were adenomatous
colonic polyp with low grade intraepithelial dysplasia and
chronic non-atrophic gastritis with moderate inflammatory
activity and intestinal focal metaplasia.
Histopathological characteristics of the 4 synchronous
tumors, in a young patient 50 years old, require the
continuation of investigations by immunohistochemical
testing to complete the diagnosis and establish a possible
syndromic classification, such as Lynch Syndrome.
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Figure 3 (A, B). Histopathological aspects of the 4
synchronous tumors (HE, x10).

Figure 3 (C, D). Histopathological aspects of the 4
synchronous tumors (HE, x10).

A: moderately differentiated tubular gastric adenocarcinoma
(G2), intestinal type (Lauren classification), stage IIB
(pT4N0Mx), with cell proliferation with medium and large
cells, with moderate cyto-nuclear atypia, which infiltrates the
entire gastric wall passing the serosa. Tumor cells show
atypical mitotic figures, some being multipolar, with severe
dyskaryosis.
B: moderately differentiated colonic (cecal) adenocarcinoma
(G2), stage IIA (pT3NoMx): large, atypical cells, with
moderate cyto-nuclear pleomorphism that form numerous
irregular glandular structures, of various sizes, with infiltrative
and destructive character on adjacent structures, without
invading the serosa. Bd1 tumor budding; absence of perineural
invasion or angio-lymphatic tumor emboli.

C: poorly differentiated colonic adenocarcinoma (splenic
flexure) (G3), stage IIA (pT3pN0Mx): numerous cellular
atypia, cyto-nuclear pleomorphism, rare small glandular and
pseudo-glandular structures with irregular appearance, typical
and atypical mitotic figures, without serous infiltration, with
Bd3 tumor budding and perineural invasion elements and
lympho-vascular emboli.
D: colonic adenocarcinoma (sigmoid), moderately
differentiated G2, stage IIB (pT3pN0Mx), with mucinous
differentiation (in 15% of cases), with extracellular mucin
lakes with basophilic tint containing glandular fragments and
groups of tumor cells, Bd2 tumor budding and perineuronal
invasion and vascular-lymphatic emboli.

The immunohistochemical
expression
pattern
performed for the 4 synchronous tumors completes and
confirms the initial diagnosis and suggests high
microsatellite instability in the MLH1 / PMS2 gene for all

tumors and MSH2 / MSH6 for the sigmoid one. The wildtype expression of p53 is a favorable prognostic element,
as is the absence of Her2neu expression in the gastric tumor
(Table 1).

Table 1. Immunohistochemical MMR pattern in the 4 synchronous tumors
Gastric tumor

Cecal tumor

Splenic flexure tumor

Sigmoid tumor

MLH1
-

-

-

-

+

+

+

-

+

+

+

-

-

-

-

-

MSH2

MSH6

PMS2

Wild-type
P53

Her2neu
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Wild-type

Wild-type

Wild-type
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BRAF V600 mutation was further tested regarding the
differentiation of sporadic colorectal cancer with high
microsatellite instability (MSI-H) from hereditary nonpolyposis colorectal carcinoma (HNPCC) or Lynch
syndrome and the result was negative, suggesting a
mutational pattern rather than inhibition by
hypermethylation of MLH1.

Discussions
Colorectal cancer is a major cause of morbidity and
mortality in the world and in Romania. Synchronous
malignancies were first described by Billroth in 1889. The
diagnostic criteria were developed in 1932 by Warren and
Gates and set out the following conditions: i) the tumors
must have histopathological confirmation of malignancy;
ii) they must be anatomically distinct (be separated from
each other by at least four cm of healthy tissue); iii) one
tumor must not be the metastasis of the other; iv) they must
be diagnosed simultaneously or at a maximum interval of
one year from each other. [1-4] The incidence of
synchronous tumors varies, in different studies, between
1.8 and 12.4%. [4] The frequency with which adenomatous
polyps are associated with colorectal cancer is 15-50%.
Known risk factors for synchronous tumors are male sex,
family history, age, and the presence of synchronous
adenomas. [2,3] Predisposing conditions are familial
adenomatous polyposis, inflammatory bowel disease, and
hereditary non-polyposis cancer (Lynch syndrome) [4-7].
Preoperative evaluation of the entire colon in patients
with colorectal cancer is important, but not always
possible. Because of this, proximal lesions synchronous
with the initial tumor may be missed. This can change the
intraoperative treatment plan or even cause a reoperation.
The undetected lesions (polyps or cancers) continue their
evolution and, at the time of subsequent diagnosis, they
appear in an advanced stage or even surgically outdated.
Synchronous colorectal cancers have rarely been studied in
large cohorts; however, the analysis of synchronous tumors
can provide special, unique data on the pathogenesis of
colon and rectal cancer [4,7].
Molecular events associated with colon carcinogenesis
During malignancy, the colonic epithelium undergoes
a series of genetic changes that are reflected in histological
changes. Genetic mutations occur long before clinically
obvious lesions. In many cancers, the cells acquire
characteristics that favor malignant transformation, but do
not produce visible morphological changes, creating only
a predisposition for cancer.[8] The modified cells form
areas of mucosa prone to malignancy; the process is called
"field cancerization" and can lead to synchronous tumors.
There are three main recognized carcinogenic
mechanisms: chromosomal instability (CIN), micro-

satellite instability (MI), involved with more than 95% of
HNPCC’s, and aberrant DNA methylation (CIMP).
Most malignancies (70-75%) occur as a result of events
that cause chromosomal instability (CIN) and progress to
the suppressive pathway. The other colon cancers are
caused by hypermethylation of the genes (the methylating
phenotype of the CpG-CIMP islands) and evolve in the
serum pathway; some of them have microsatellite
instability (MSI), and the development of the latter takes
place on the mutant path. One of the earliest changes in
both oncogenesis pathways (MSI and CIN) is the loss of
APC gene function, which predisposes people with germline mutations in APC to develop colon cancer [6-9].
Approximately 15% of colorectal adenocarcinomas are
associated with MSI: 2.5% coming from a genetic
inheritance and 12.5% being sporadic. [10]
Mismatch repair (MMR) genes and Microsatellite
instability (MSI)
Microsatellite instability (MSI) is due to altered
expression of MMR genes (mismatch repair), involved in
the processes of recognition and repair of microsatellite
errors during DNA synthesis to maintain genomic stability.
There are 4 MMR genes and their encoded proteins, which
form heterodimers 2 by 2: MLH1 / PMS2 and MSH2 /
MSH6. Inactivation of MLH1 and MSH2 account for over
90% of deficient MMR cases. If any of the four major
proteins (MSH2, MLH1, MSH6, or PMS2) is functionally
inactive, mismatches are not repaired. A defective DNA
MMR system increases the mutation rate and makes the
cell vulnerable to mutations in genes controlling cell
growth (including tumor suppressor genes and oncogenes),
resulting in an elevated cancer risk. [11,12]
Immunohistochemical analysis revealed that when
MLH1 or MSH2 is nonfunctional, their corresponding
peers will also appear negative, as they disintegrate without
their obligatory partners. In contrast, inactivation of MSH6
or PMS2 does not lead to absence of MSH2, respectively
MLH1, as these proteins can dimerize also with other
proteins, for example MLH3[11].
Sporadic MSI is caused more frequently by epigenetic
silencing of the MLH1 promoter by methylation, which is
associated with a somatic BRAF V600E mutation.
Hereditary MSI commonly happens due to autosomal
dominant mutations in MMR. Lynch syndrome is
associated in 90% of cases with MLH1 or MSH2 mutations
[13].
In the presented case, the immunohistochemical pattern
associated with the absence of the BRAF V600 mutation is
suggestive of the MLH1 mutation in all 4 tumors, and, in
addition, of MSH2 in the sigmoid tumor.
Testing the mismatch repair genes (MMR) profile by
immunohistochemistry is particularly important for
253
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understanding the mechanism of carcinogenesis, planning
cancer treatment, and evaluating the prognosis in
synchronous digestive cancers. [14] The criteria for
recommending testing for MSI are, according to the Dutch
guideline for MSI testing (http://www.oncoline.nl):
1. CRC or endometrial carcinoma before the age of 50
years.
2. A second CRC before the age of 70 years.
3. CRC before the age of 70 years AND another
synchronous or previous Lynch Syndrome associated
tumor
Clinical and prognostic features of MSI-H colorectal
tumors
Cancers associated with MSI-H have special
characteristics from a histopathological point of view; they
are generally adenocarcinomas with medium-weak
differentiation, with possible mucinous component and
important associated inflammatory lymphocytic infiltrate.
They are predominantly located on the right side of the
colon [15,16].
Patients with MSI-H tumors have been associated with
a more favorable prognosis compared to patients with MSIL or MSS tumors, a significantly lower likelihood of
metastasizing to regional lymph and distant organs [17,18].
Given our current level of understanding, this favorable
prognosis could not be fully explained only by molecular
mechanisms, but studies correlate better survival with the
presence of lymphocytic infiltration seen in MSI-H tumors,
an expression of an enhanced host immune response
invoked by the presence of numerous mutated products
[19-22].
Others have also suggested that the enormous
mutational burden resulting from loss of MMR activity
may be self-limiting in that essential cell functions may be
hindered [16,21-23]. Regarding the response to 5-FU, it is
considered that in stage II chemotherapy is not necessary
for MSI-H tumors. The favorable prognosis and the
evidence of lack of benefit from 5-FU based adjuvant
chemotherapy in stage II CRC patients with deficient
MMR indicate that these patients should not receive
adjuvant chemotherapy. In stage III CRC, however,
patients with deficient MMR cancers treated with adjuvant
5-FU had better outcomes. In stage III colon cancer
patients, oxaliplatin combined with 5-FU is the current
standard of care for adjuvant chemotherapy. In contrast to
5-FU, sensitivity to oxaliplatin was independent of the
MMR system in CRC cell lines [24-26]. The absence of
BRAF mutation expression is a favorable prognostic factor
[27,28].
The particularity of the case resides in the absence of
any family history of CRC and the lack of digestive
symptoms. These led to the accidental detection of the
254

colon tumors by CT examination, followed by subsequent
exploration, but without paying preoperatory attention to
upper digestive tract [29]. However, rare “de novo” cases
of Lynch syndrome have been reported and prompted early
familial screening potentially preventing CRC associated
morbidity.
Incomplete possibilities of preoperative assessment,
due to the stenotic behavior of splenic flexure tumor, led to
intraoperative change of the surgical plan. Although bulky,
tumors had histopathological and immunohistochemical
features which were statistically associated with favorable
prognosis. Regular follow-up in the surgical department is
necessary for screening of recurrent tumors or
metachronous cancers. [30-32].

Highlights
✓ Careful pre- and intraoperative evaluation of patients
with suspected synchronous cancers is particularly
important in therapeutic planning.
✓ MSI represents a promising disease marker for
colorectal cancers because of the favorable prognosis
associated with MSI-H and particularities of
oncological management.

Conclusions
Careful pre- and intraoperative evaluation of patients
with suspected synchronous cancers is of paramount
importance in therapeutic planning. Additionally,
employment of IHC testing for surrogate gene mutations
identification represents a promising complementary tool
for improvement of prognostic assessment and tailored
oncological treatment.
Although more than 75% of colorectal cancers are
sporadic, identification of familial and hereditary CRC
could increase the efficacy of screening programs and
reduce the economic pressure exerted on health systems
worldwide. The perspective of developing new treatment
options and optimized guidelines for CRC can become a
reality only by incorporating gene assessment and ultrastratification of patients.
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